Craig Coleman
Professor/Pharmacy Practice

Are you Craig Coleman?

How to update your information.
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
2024
Craig Coleman, B Schaefer, M Carrier, C Ay, C Wallenhorst, M Rivera, A Ekbom, G Brobert, A T Cohen, K Abdelgawwad, C Martinez, G Psaroudakis, C Becattini, A A Khorana
Research Type: Journal Article

Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model.
2024
William L Baker Jr., M J Christoph, B Koch, M Ouwens, G Frady, Craig Coleman, A Cohen, M Sharma, T E Moore
Research Type: Journal Article

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
2024
K Rhodes, Charles M White, Craig Coleman, H van Haalen, Youssef Bessada, K S Caroti, Adrian V Hernandez Diaz, P P Dobesh, William L Baker Jr.
Research Type: Journal Article

Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial data.
2024
M J Christoph, A T Cohen, B Koch, William L Baker Jr., Craig Coleman, M Concha, B Lovelace
Research Type: Journal Article

Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
2024
G Brobert, C Becattini, K Vogtländer, M Linder, Craig Coleman, M Carrier, A A Khorana, A Ekbom, D H Giunta, Y Balabanova, A T Cohen, M Rivera, K Abdelgawwad, B Schaefer, G Psaroudakis
Research Type: Journal Article

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
2023
K S Caroti, B Schaefer, K Abdelgawwad, A T Cohen, M Carrier, C Brescia, A A Khorana, M Rivera, Craig Coleman, C Becattini, G Psaroudakis, A Ekbom, G Brobert
Research Type: Journal Article

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
2023
G Brobert, C Becattini, B Schaefer, Craig Coleman, K Abdelgawwad, M Carrier, A A Khorana, K S Caroti, G Psaroudakis, C Brescia, A Ekbom, M Rivera, A T Cohen
Research Type: Journal Article

Derivation and validation of a composite scoring system (SAVED(2)) for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage.
2023
A T Cohen, M J Christoph, B Koch, M Concha, Craig Coleman, B Lovelace
Research Type: Journal Article

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
2023
B Schaefer, S Fatoba, G Brobert, A Ekbom, M Rivera, G Psaroudakis, C Brescia, K Abdelgawwad, K S Caroti, C Becattini, Craig Coleman, M Carrier, A T Cohen, A A Khorana
Research Type: Journal Article

Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries.
2023
Craig Coleman, B Lovelace, J M Williams, M J Christoph, H Guo, S Li, M Hoover
Research Type: Journal Article

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
2023
Craig Coleman, H Chen, E Lesén, B Koch, J Ulloa, M Danese, P P Dobesh, T Dettling, G J Fermann, S Danese, M J Christoph, B Lovelace
Research Type: Journal Article

Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea.
2023
Youssef Bessada, V Ashton, B K Bookhart, Katelyn Galli, Craig Coleman, N Sood
Research Type: Journal Article

Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies.
2023
B K Bookhart, Craig Coleman, V Ashton, M S Roberts, K S Caroti, Youssef Bessada, William L Baker Jr.
Research Type: Journal Article

Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
2022
Craig Coleman, Thomas Bunz, V Ashton
Research Type: Journal Article

Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.
2022
B Schaefer, Craig Coleman, B Vardar, F Kleinjung, T Vaitsiakhovich
Research Type: Journal Article

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
2022
Craig Coleman, William L Baker Jr., A A Kharat, B Bookhart
Research Type: Journal Article

A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.
2022
C W Brescia, O S Costa, B Vardar, N Sood, Craig Coleman, L Hofmeister, K Abdelgawwad
Research Type: Journal Article

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
2022
B Lovelace, Craig Coleman, M Sharma, J Beyer-Westendorf, O S Costa, M J Christoph, S J Connolly
Research Type: Journal Article

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
2021
N Sood, O S Costa, Craig Coleman, C W Brescia, B Vardar, K Abdelgawwad
Research Type: Journal Article

Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
2021
Craig Coleman, B Vardar, B O'Donnell, N Sood, C W Brescia, O S Costa, K Abdelgawwad
Research Type: Journal Article